Retatrutide
10mg vial. Triple receptor agonist.
// tl;dr
An experimental weight-loss molecule. Goes a step beyond Ozempic and Mounjaro by targeting three hormones at once instead of one or two.
// about
Phase III triple-agonist targeting GLP-1, GIP, and glucagon receptors. The glucagon component differentiates it from mono- and dual-agonists like Semaglutide and Tirzepatide. Research-only; not FDA approved. 10mg lyophilized peptide.
// structure
- hydrophobic
- polar
- positive
- negative
- special
39 residues. GLP-1/GIP/glucagon triple-receptor agonist with a fatty-acid sidechain. The morph cycles through plausible low-frequency conformations - illustrative flexibility, not the experimentally resolved ensemble. Bead brightness scales with per-residue RMSF: the dimmer the residue, the more rigid it is in the ensemble.
// questions
// for research purposes only. not for human consumption.
// not intended to diagnose, treat, cure, or prevent any disease.